Log in

NASDAQ:VIVEViveve Medical Stock Price, Forecast & News

-0.02 (-3.44 %)
(As of 07/3/2020 04:00 PM ET)
Today's Range
Now: $0.56
50-Day Range
MA: $0.63
52-Week Range
Now: $0.56
Volume359,058 shs
Average Volume1.06 million shs
Market Capitalization$8.78 million
P/E RatioN/A
Dividend YieldN/A
Viveve Medical, Inc. designs, develops, manufactures, and markets medical devices for the non-invasive treatment of various post-partum conditions. The company offers Viveve System, a radio frequency generator, a reusable hand piece, and single-use treatment tip, as well as other consumable components. It markets its products through sales employees and distributors in the United States, the Asia Pacific, Europe, the Middle East, Latin America, and Canada. Viveve Medical, Inc. was founded in 2005 and is headquartered in Englewood, Colorado.
Read More
Viveve Medical logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.0Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.05 out of 5 stars

Industry, Sector and Symbol

Industry Electromedical equipment
Current SymbolNASDAQ:VIVE
Previous SymbolOTCMKTS:PLCSD



Sales & Book Value

Annual Sales$6.57 million
Book Value$2.34 per share


Net Income$-42,530,000.00
Net Margins-822.47%
Return on Equity-25,840.09%


Market Cap$8.78 million
Next Earnings Date8/13/2020 (Estimated)

Receive VIVE News and Ratings via Email

Sign-up to receive the latest news and ratings for VIVE and its competitors with MarketBeat's FREE daily newsletter.

Viveve Medical (NASDAQ:VIVE) Frequently Asked Questions

How has Viveve Medical's stock been impacted by COVID-19 (Coronavirus)?

Viveve Medical's stock was trading at $0.84 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, VIVE shares have decreased by 33.2% and is now trading at $0.5612. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Viveve Medical?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viveve Medical in the last year. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Viveve Medical.

When is Viveve Medical's next earnings date?

Viveve Medical is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Viveve Medical.

How were Viveve Medical's earnings last quarter?

Viveve Medical Inc (NASDAQ:VIVE) issued its quarterly earnings results on Thursday, May, 14th. The company reported ($0.82) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($12.60) by $11.78. The firm had revenue of $1.30 million for the quarter. Viveve Medical had a negative return on equity of 25,840.09% and a negative net margin of 822.47%. View Viveve Medical's earnings history.

What price target have analysts set for VIVE?

5 analysts have issued 12 month price targets for Viveve Medical's shares. Their forecasts range from $0.20 to $1.00. On average, they anticipate Viveve Medical's share price to reach $0.60 in the next twelve months. This suggests a possible upside of 6.9% from the stock's current price. View analysts' price targets for Viveve Medical.

What are Wall Street analysts saying about Viveve Medical stock?

Here are some recent quotes from research analysts about Viveve Medical stock:
  • 1. According to Zacks Investment Research, "Viveve Medical, Inc. is a medical device company focused on technologies for the cardiac and vascular markets. The Company's lead product, RenalGuard (R), is designed to remove contrast dyes that are known to be toxic to the kidneys. Viveve Medical Inc., formerly known as PLC Systems Inc., is headquartered in Milford, Massachusetts. " (5/22/2020)
  • 2. Maxim Group analysts commented, "Yesterday, after the Market close, VIVE reported 2Q19 revenue inline with our estimates adjusted for the preannouncement on July 22, 2019, but lower than consensus." (8/9/2019)

Has Viveve Medical been receiving favorable news coverage?

News articles about VIVE stock have been trending negative this week, according to InfoTrie. The research group scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Viveve Medical earned a coverage optimism score of -2.2 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the stock's share price in the immediate future. View the latest news about Viveve Medical.

Who are some of Viveve Medical's key competitors?

What other stocks do shareholders of Viveve Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Viveve Medical investors own include Corbus Pharmaceuticals (CRBP), Visa (V), Fortive (FTV), HP (HPQ), Lowe's Companies (LOW), Western Digital (WDC), SCYNEXIS (SCYX), Viking Therapeutics (VKTX), Inovio Pharmaceuticals (INO) and Novavax (NVAX).

Who are Viveve Medical's key executives?

Viveve Medical's management team includes the following people:
  • Mr. Scott C. Durbin, CEO & Director (Age 50)
  • Mr. James Gregory Atkinson, Chief Bus. Officer & Pres (Age 61)
  • Mr. Jim B. Robbins, VP of Fin. & Admin., Principal Accounting Officer and Principal Financial Officer (Age 55)
  • Ms. Deborah A. Jorn, Sr. Advisor to the CEO & Director (Age 61)
  • Mr. Martin Kerber, VP of Operations

When did Viveve Medical IPO?

(VIVE) raised $13 million in an IPO on Tuesday, June 14th 2016. The company issued 1,600,000 shares at $8.00 per share. Ladenburg Thalmann and Craig-Hallum Capital Group acted as the underwriters for the IPO and Maxim Group was co-manager.

What is Viveve Medical's stock symbol?

Viveve Medical trades on the NASDAQ under the ticker symbol "VIVE."

How do I buy shares of Viveve Medical?

Shares of VIVE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Viveve Medical's stock price today?

One share of VIVE stock can currently be purchased for approximately $0.56.

How big of a company is Viveve Medical?

Viveve Medical has a market capitalization of $8.78 million and generates $6.57 million in revenue each year. The company earns $-42,530,000.00 in net income (profit) each year or ($33.80) on an earnings per share basis. Viveve Medical employs 67 workers across the globe.

What is Viveve Medical's official website?

The official website for Viveve Medical is www.viveve.com.

How can I contact Viveve Medical?

Viveve Medical's mailing address is 345 INVERNESS DRIVE SOUTH BUILDING B SUITE 250, ENGLEWOOD CO, 80112. The company can be reached via phone at 720-696-8100 or via email at [email protected]

This page was last updated on 7/5/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.